Innovus Pharma Announces the Approval of its Product ProstaGorx in Canada for Benign Prostate Hyperplasia ("BPH")

ProstaGorx is the Ninth Innovus Pharma Product Approved in Canada to Date

SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire – Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market:INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced the approval by Health Canada of its product ProstaGorx as a Natural Health Product (NPN # 80085717) for the relief of urologic symptoms (e.g. weak urine flow, incomplete voiding, frequent daytime and night time urination) associated with mild to moderate benign prostatic hyperplasia (“BPH”). Innovus Pharma expects to launch ProstaGorx in the next few months through the Company’s website and its Canadian Beyond Human marketing and sales platform.

“We are very delighted with the approval of ProstaGorx for the BPH indication in Canada,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “We currently expect ProstaGorx to perform very well in Canada and look forward to its launch in the very near future. ProstaGorx when launched, will be the fourth product launched through our own sales and marketing commercial efforts in Canada in addition to Vesele, Apeaz and Xyralid and when launched will then be our eighth product on the Canadian market including Zestra, Zestra Glide and Uxor (EjectDelay) marketed by Orimed Pharma and UriVarx through our partnership with Acerus Pharmaceuticals Corporation. Another of the Company’s products, AllerVarx, a supplement for allergic rhinits, has been approved by Health Canada, but has not yet launched.”

About the BPH Market

An estimated 50% of men have histologic evidence of BPH by age 50 and 75% by age 80; in 4050% of these men, BPH becomes clinically significant. BPH was one of the ten most common, and costly, diseases in men older than 50 years of age in a recent study in the United States. The Canadian market is estimated to be 10% of the US market size.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the ProstaGorx product in Canada, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.

Contact:

Randy Berholtz

Innovus Pharma Investor Relations

Tel: +1 858 249 7865

ir@innovuspharma.com